Use the Back button in your browser to see the other results of your search or to select another record.

Detailed Search Results

The effectiveness of trigger point injection plus Kinesio Taping in myofascial pain syndrome: a randomized, sham-controlled clinical trial
Yilmaz E
Muscles, Ligaments and Tendons Journal 2021 Apr-Jun;11(2):251-258
clinical trial
5/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: No; Baseline comparability: Yes; Blind subjects: No; Blind therapists: No; Blind assessors: Yes; Adequate follow-up: No; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*

OBJECTIVE: Although the trigger point injection (TPI) is the most widely used treatment method in myofascial pain syndrome (MPS), other treatment methods have also been proven to be influential. Even if a certain level of pain relief is achieved after the TPI, this effect persists for a short time and a few treatment sessions are generally required. Hence, a multidisciplinary approach to treatment seems to be most useful. Therefore, this study aimed to evaluate the efficacy of the combination of TPI with Kinesio Taping (KT) on the trapezius muscle in the treatment of MPS. METHODS: 50 patients with MPS were randomly separated into two groups (25 patients per group): group 1: TPI+KT; group 2: TPI plus sham KT. Visual analog scale (VAS) and neck disability index (NDI) were recorded at baseline and 1, 3 months post-treatment. RESULTS: The mean age of patients was 42.5 +/- 13.89 and 43.8 +/- 12.23 years in group 1 and group 2, respectively. In group 1, pre- and post-treatment (at 1 and 3 months) VAS/NDI scores were 8.0 +/- 0.45/40.96 +/- 1.27, 0.08 +/- 0.28/7.51 +/- 2.55, and 0.44 +/- 0.51/8.96 +/- 3.27, respectively. In group 2, pre- and post-treatment (at 1 and 3 months) VAS/NDI scores were 8.0 +/- 0.54/41.21 +/- 1.54, 0.25 +/- 0.44/8.35 +/- 2.75, and 2.33 +/- 1.44/13.98 +/- 5.63, respectively. VAS and NDI scores at 3 months were significantly lower in group 1 versus group 2 (p < 0.05). CONCLUSIONS: The complex pathology with underlying peripheral and central neural mechanisms of MPS might conduce to the difficulties within the treatment of MPS, especially within the chronic period. The combined therapy appears to generate a more influential outcome for a long run than monotherapy in alleviating pain and reforming functional amelioration in the management of MPS.

Full text (sometimes free) may be available at these link(s):      help